| INTRODUCTION
To help better direct dermatopathologists in their use of ancillary tests, the American Society of Dermatopathology (ASDP) created the Appropriate Use Criteria (AUC) Task Force in 2015. The AUC Task Force was divided into four subgroups that each chose to examine 2 to 3 ancillary tests. As a part of this effort, a synopsis of the evidence behind each test was performed. 1 The reviews for each of the four subgroups are intended to be a review of the literature and highlight the data obtained during Short Course I "Best Practices" at the 51st annual meeting of the ASDP. These reviews do not have any specific recommendations.
The separate manuscript that details the evidenced-based criteria to assist ordering professionals in making the most appropriate utilizations decisions for specific clinical conditions has now been published. The gold standard for the diagnosis of melanocytic lesions is histologic examination. However, as histologic examination can have its limitations, there are many clinical scenarios in which additional testing may be appropriate in an attempt to render a definitive diagnosis.
The clinical management and prognosis for the patient depends on the ability to accurately diagnose melanocytic lesions. The Melanocytic Subgroup of the ASDP AUC Task Force chose to explore the appropriate use of CGH/SNP array, FISH, and qRT-PCR assays.
| CGH/SNP arrays
CGH is a molecular method that can analyze the entire genomic DNA in cells for copy number changes. Two techniques are generally employed. In one, a fluorochrome (usually green) is used to label tumor DNA. The labeled DNA is then mixed in a 1:1 ratio with a reference DNA from normal tissue that has been labeled with a different fluorochrome (usually red). The mixture is subsequently hybridized onto normal metaphase spreads (classic CGH) or hybridized onto a microarray of mapped clones of genomic DNA (array CGH; aCGH).
The metaphase chromosomes or the microarrays are washed and then scanned. A green color at a certain locus indicates excess tumor DNA compared to normal and therefore a gain of that region, red color indicates a DNA loss, and yellow color indicates normal copy number compared to the normal reference. In the last decade, aCGH has largely replaced classic CGH because of its higher resolution, reproducibility, and robustness. In the second technique, only tumor DNA is labeled with a reporter fluorochrome and hybridized onto a microarray. Similar to the prior protocol, the arrays are washed and scanned.
The copy number status at a certain locus is determined by comparing the signal intensity with a reference from a control series of normal tissues. More recently, SNP microarray platforms have emerged as alternatives to CGH. SNP platforms are able to provide allele frequency data as well as information regarding copy number changes.
These platforms can detect copy neutral loss of heterozygosity events and can be designed to identify selected mutations. Protocols using molecular inversion probes specifically designed to work with low quantities of degraded DNA from formalin-fixed paraffin embedded tissue have also been developed in the last years. 2, 3 The utility of CGH/SNP arrays is based on the principle that most melanomas to have an unstable genome with numerous chromosomal structural abnormalities while the majority of melanocytic nevi do not display chromosomal aberrations or show specific isolated abnormalities (such as 11p gains in Spitz nevi). [4] [5] [6] [7] This non-overlapping pattern of chromosomal aberrations provided an opportunity for diagnostic strategies based on tests evaluating DNA copy number alterations such as CGH/SNP arrays. Figure 1 highlights an example of a case where SNP microarray was performed. 15 This includes one gene specific to melanocytic differentiation (PRAME), eight genes implicated in immune signaling (CCL5, CD38, CXCL10, CXCL9, IRF1, LCP2, PTPRC, and SLL), five genes with multifunctional roles (S100A9, S100A7, S100A8, S100A12, and PI3), and nine house- The scientific evidence behind the use of CGH, FISH, and qRT-PCR for melanocytic lesions in dermatopathology was performed, itemized, and summarized. In addition, an audience response system was used at the beginning of Short Course I "Best Practices" at the 53rd annual meeting of the ASDP in Chicago, Illinois, to explore the practice patterns of these molecular assays in the attendees of the course.
| MATERIALS AND METHODS

| Evidence review
Journals written in English from the years 2000 to 2016 were searched in PubMed to find and assess the use of molecular testing (FISH, CGH, and qRT-PCR) in melanocytic neoplasia. The articles were searched using "melanoma," "melanocytic neoplasm," and "melanocytic nevus/nevi" as major keywords that were then overlapped with the specific modes of molecular testing (FISH, CGH, and qRT-PCR). Only articles that mostly examined cutaneous melanomas were included. Articles dealing with non-cutaneous melanomas (e.g., uveal)
were excluded, with the exception of anal and conjunctival melanoma.
Both case series of fewer than three cases and individual case reports were excluded in the analysis. Research focusing on melanoma cell lines was also excluded. 
| Practice pattern assessment
The practice patterns of attendees of Short Course I "Best Practices"
during the 53rd Annual meeting of the ASDP in Chicago, Illinois for their use of molecular testing in melanocytic lesions was evaluated using an audience response system. This was performed via a webbased platform (Poll Everywhere) that allows participation via a smartphone, tablet, or other internet-connected device by anyone in the audience. The audience was polled prior to presentation of evidence review.
| COMMENTS AND CONCLUSIONS
In the dawn of molecular analysis, the genetic exploration of melanocytic lesions led to the discovery that melanomas contain chromosomal gains at 1q, 4q, 6p, 7q, 11q, 17q, and 20q, as well as chromosomal deletions including 9p, 10, and 21q. Gains in 6p were found to be specifically associated with an unfavorable prognosis.
Analysis of Spitz nevi highlighted that the majority of Spitz nevi do not show genomic aberrations; about 20% of Spitz nevi show gains in 11p. These crucial discoveries provided the foundation for future studies using the testing modalities described herein, and the commencement of the use of molecular diagnostic tools as an adjunct to histology. The key goals of these tests are to provide more accurate characterization of melanocytic lesions and provide some insight into prognosis. 4, 6 This review summarizes the scientific evidence related to the use of CGH/SNP arrays, FISH and qRT-PCR in melanocytic lesions since these pivotal discoveries.
| CGH in cutaneous melanocytic lesions since the year 2000
Within the literature review, there were 23 articles identified. The majority of these studies were retrospective case series. The number of specimens in the studies ranged from 3 to 186 with a total number (Table S1 in Appendix S1 in the Supporting Information).
Early cytogenetic studies of melanocytic lesions helped to provide the rationale behind the utility of CGH as an ancillary tool in melanocytic lesions and highlighted the differences between nevi and mela- (Table S2 in Supporting Information). 25, 26 In general, FISH testing for melanoma is a multiplex assay including probes targeting loci that have been found to be frequently altered through CGH technology. 27 The clinical utility of FISH has been explored in a number of studies. While many studies have evaluated differences between nevi and melanoma, there are also an abundance of articles looking at ambiguous or controversial lesions. 20, 21, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Likewise, studies have confirmed the usefulness of FISH in the differentiation of conjunctival nevi from melanoma, 38 epithelioid blue nevi from blue nevus-like cutaneous melanoma metastasis 39 and in melanocytic lesions with a large epithelioid component. 40 FISH has also been used in the distinction of Spitz nevi from spitzoid melanoma. 41 Similarly, the utility of FISH in differentiating nodal nevi from metastatic melanoma has been reported. 42 However, caution must still be used as limitations of this test have been identified. Certain melanoma subtypes have a higher rate of false-negative FISH results using the standard panel; therefore, more research may be needed to develop probes that yield higher sensitivities. One such example is the utility of FISH in distinguishing sclerosing nevi from desmoplastic melanoma. A positive FISH result is helpful in confirming melanoma, but a negative result does not equate with benignancy. 43 The standard FISH panel has evolved over time. An initial study investigated the performance of 14 FISH probes targeting the loci most commonly altered in melanoma. 27 Using sets of unequivocal lesions (benign and malignant), the authors determined that a panel of probes targeting 6p25 (RREB1), centromere 6, 6q23 (MYB), and 11q13 (CCND1) provided the highest discrimination between the two groups with a sensitivity and specificity of 86.7% and 95.4%, respectively.
The test uses a scoring algorithm that involves evaluation of at least (MYC). 45 It has been proposed that adding these probes to the original probe set increases sensitivity to 94% and specificity to 98% for these lesions. In addition, it has been proposed that this probe set provides prognostic information in borderline spitzoid tumors. 46 It should be noted that these values have not yet been replicated in large subsequent studies so -as with all new ancillary tests in diagnostic pathology -these may be judged with caution at this point in time.
Overall the literature shows a relatively high sensitivity and specificity for FISH with the sensitivity ranging from 85% to 100% and the specificity ranging from 90% to 98%. The variation is because of the probe set used for the assay and the cutoff thresholds set. These ranges are significantly lower for ambiguous lesions, where the sensitivity and specificity are 43% to 100% and 33% to 89%, respectively.
While it is clear when reviewing the literature that FISH is not able to
give a definitive answer of benign or malignant, it does appear that in certain clinical scenarios, FISH may be informative as an ancillary study.
The prognostic significance associated with FISH in melanocytic lesions has also been studied. In looking at paired primary and metastatic melanomas, primaries that were FISH positive had a higher rate of metastasis and melanoma-associated deaths compared with FISHnegative cases, although in this study only the primary melanoma was studied with FISH. 47 Research has shown that gains in 11q13 and 8q24 are thought to be predictive of metastasis. 48 Likewise, in a study examining atypical spitzoid tumors with borderline histology, cases with homozygous losses of 9p21, gains in 6p25 or 11q13 were at a higher risk for aggressive clinical behavior compared to atypical spitzoid tumors that were FISH negative or had isolated 6q23 deletions that did not show clinical progression. (Table S3) .
The two validation studies suggest qRT-PCR has a sensitivity of 90% to 91.5% and a specificity of 91% to 92.5% for melanoma. 25, 50 In one study, there was 97% and 83% concordance with histology for FISH and qRT-PCR in a group of unequivocal melanocytic lesions resulting in a sensitivity and specificity of 93% and 100% for FISH and 62% and 95% for qRT-PCR. The intertest agreement was found to be 80%. 51 In another study, for diagnostically challenging cases initially diagnosed as indeterminate by histomorphology and immunohistochemistry, definitive diagnoses increased by 56.6% following qRT-PCR testing. 52 As the literature for qRT-PCR is in its infancy, future studies will probably dictate the utility and clinical scenarios where this ancillary test may be helpful.
| Practice patterns of FISH, CGH, and qRT-PCR in cutaneous melanocytic lesions
To identify the practice patterns of CGH, FISH, and qRT-PCR, an audience response system was used to survey attendees of Short Course I "Best Practices" during the 53rd annual meeting of the ASDP (Chicago, Illinois, 2016). The number of respondents ranged from 167 to 176 for each question related to molecular testing of melanocytic lesions. It is difficult to provide a precise overview of the expertise level of these participants and "expertise" certainly has an element of subjectivity. This could be considered a limiting factor in the interpretation of the results. But given the nature of this subspecialty conference, it can be assumed that the vast majority were practicing dermatopathologists or dermatopathologists in training. Fifty-four percent of respondents reported routine use (or expecting consultants to use) of molecular testing for ambiguous melanocytic lesions with an additional 37% reporting rare use (less than five time each year), while only 8% of respondents never used molecular testing for this scenario.
Not surprisingly, only 31% of respondents reported performing molecular testing at their practice or institution, with an additional 59% report using outside labs to perform these tests. This probably reflects the technical difficulty in performing these assays and the fact that qRT-PCR is generally only available as a send out test (Table 1) .
While cost is not a factor when creating AUC, more than half (54%) of respondents report "almost always" considering insurance or patient-related costs prior to ordering molecular testing for melanocytic lesions and only 27% rarely consider cost. Because cost is a significant factor in ordering these ancillary studies, criteria that identify clinical scenarios where testing improves diagnosis and outcomes with a high degree of specificity and sensitivity will be helpful to practicing dermatopathologists.
To reiterate, this article is intended to be a review of the literature and highlight the data obtained during Short Course I "Best Practices" at the 51st annual meeting of the ASDP. This review does not have any specific recommendations. As the work of the AUC task force of the ASDP continues, appropriateness ratings to better help guide dermatopathologists in the selection of these tests in commonly encountered scenarios in clinical practice will be reported.
